Lozanovski · 2020 · Investigational new drugs
Findings from the sprout capsule trial in pancreatic cancer
What outcomes were observed when broccoli sprout capsules were added during chemotherapy?
Human · POUDER pilot trial
Key findings
Survival follow-up results
In a pilot trial of 40 patients with advanced pancreatic cancer, the 180-day mortality rate was 25% in the intake group and 43% in the placebo group. The between-group difference was not statistically significant (p=0.291).
Mortality at 180 Days
Reported proportion by group · %
p = 0.291 · no significant survival effect established
Placebo 11 / intake 29 · high dropout
Read the original paper and sources ↓View values and units
| Group | Value |
|---|---|
| Placebo | 43 |
| Intake group | 25 |
Study design
Of 40 patients with advanced pancreatic cancer, 29 in the intake group and 11 in the placebo group were followed for up to one year. Fifteen daily capsules contained SFN 90mg and GLR 180mg; actual allocation and maintenance of blinding had limitations.
- Participants
- Germany · 40 patients with advanced pancreatic cancer
intake 29 / comparison 11
during chemotherapy · pilot trial - Intake and observation
- Sprout powder capsules · up to one year
15 capsules daily: sulforaphane 90mg
+ glucoraphanin 180mg - Measures
- Feasibility of intake · dropout · survival
Study context
The one-year dropout rate was 72% in the intake group and 55% in the placebo group. Patient preference affected allocation, and blinding was not maintained.
Observed during intake: The burden of taking 15 capsules daily and digestive discomfort, nausea, and vomiting were reported.
Original paper and sources
Broccoli sprout supplementation in patients with advanced pancreatic cancer is difficult despite positive effects-results from the POUDER pilot study.
- Journal
- Investigational new drugs · 2020 · 38(3): 776-784
- First published
- 2019-06-27